EZH2: An analysis of a potential new tumor marker in high-risk localization of cutaneous squamous cell carcinomas
The hypothesis of the predictive prognostic contribution of EZH2 in clinical decisions regarding the occurrence of LNM was not substantiated by our data. Nevertheless, the elevated expression of EZH2 we have observed in our findings could be utilized as a pretherapeutic assessment prior to targeted therapies with tazemetostat. Subsequent research should substantiate this hypothesis.
Authors
- Christian Hallermann (ORCID: https://orcid.org/0000-0003-1620-1723)
- Jan-Dirk Raguse
- M. Klein (ORCID: https://orcid.org/0000-0003-0569-645X)
- Kai Wermker (ORCID: https://orcid.org/0000-0001-8284-217X)
- Hans‐Joachim Schulze (ORCID: https://orcid.org/0000-0001-7689-2816)
- Cristian-Viktor Valea
Institutions
- Institut für Hämatopathologie Hamburg (DE)
- Klinikum Osnabrück (DE)
- Fachklinik Hornheide (DE)
- RWTH Aachen University (DE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.3389/fonc.2024.1438021
- Citations
- 2
- Primary Topic
- Tumors and Oncological Cases
- Type
- article
- Field-Weighted Citation Impact
- 2.94